Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) FCF Margin (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed FCF Margin for 6 consecutive years, with 3.51% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin rose 17.0% year-over-year to 3.51%, compared with a TTM value of 2.39% through Dec 2025, down 1496.0%, and an annual FY2025 reading of 2.39%, down 1496.0% over the prior year.
  • FCF Margin was 3.51% for Q4 2025 at Cytek Biosciences, up from 8.71% in the prior quarter.
  • Across five years, FCF Margin topped out at 28.63% in Q3 2024 and bottomed at 22.19% in Q2 2022.
  • Average FCF Margin over 5 years is 0.29%, with a median of 0.49% recorded in 2024.
  • The sharpest move saw FCF Margin skyrocketed 3759bps in 2024, then tumbled -3734bps in 2025.
  • Year by year, FCF Margin stood at 13.66% in 2021, then tumbled by -150bps to 6.87% in 2022, then surged by 339bps to 16.43% in 2023, then crashed by -80bps to 3.34% in 2024, then increased by 5bps to 3.51% in 2025.
  • Business Quant data shows FCF Margin for CTKB at 3.51% in Q4 2025, 8.71% in Q3 2025, and 3.22% in Q2 2025.